Clinical Trials

The Cancer Center offers patients access to a wide variety of clinical trials of promising new therapies. Use the search tool below to find open protocols for your type of cancer. To learn more about eligibility and participation call 877-789-6100.

Search by conditions: 

Click a protocol # to view extended details on a particular clinical trial.

Protocol #DescriptionPhase
15-1051205-01: A Phase 1 Study of CPI-1205, a Small Molecule Inhibitor of EZH2, in Patients with B-Cell Lymphomas  (View details on I
14-191A Phase 1 Study of CPI-0610, a Small Molecule Inhibitor of BET Proteins, in Patients with Acute Leukemia, Myelodysplastic Syndrome, or Myelodysplastic/Myeloproliferative Neoplasms  (View details on I
12-461A Phase 1, Open-Label, Dose-Escalation Study of SGN-CD19A in Patients With B-Lineage Acute Lymphoblastic Leukemia and Highly Aggressive Lymphomas  (View details on I
14-566A Phase 2 Study of Pembrolizumab (MK-3475) After Autologous Stem Cell Transplantation in Patients With Relapsed/Refractory Classical Hodgkin Lymphoma and Diffuse Large B Cell Lymphoma  (View details on II
12-321A Phase 2, Controlled Trial, of a Single ProHema-CB Unit (Ex Vivo CXCR4-Upregulated CD34+ Hematopoietic Progenitor Cells, Cord Blood) as Part of a Double Umbilical Cord Blood Transplant Following Myeloablative Conditioning for Patients Age 15-55 Years with Hematologic Malignancies  (View details on II
14-059A Phase 3 Extension Study of Duvelisib and Ofatumumab in Patients With Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma Previously Enrolled in Study IPI-145-07  (View details on III
13-539A Phase 3 Study of IPI-145 Versus Ofatumumab in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma  (View details on III
06-068A Phase I Safety, Pharmacokinetic and Pharmacodynamic Study of PF-02341066. A CMET/HGFR Selective Tyrosine Kinase Inhibitor, Administered Orally To Patients With Advanced Cancer  (View details on I
13-348A Phase I Study of CPI-0610, a Small Molecule Inhibitor of BET Proteins, in Patients with Progressive Lymphoma  (View details on I
14-296A Phase II Study of Ibrutinib in Combination with Fludarabine, Cyclophosphamide, and Rituximab (iFCR) in Previously Untreated, Younger Patients with Chronic Lymphocytic Leukemia  (View details on II
13-309A Phase II Study of Idelalisib (GS1101, CAL101) + Ofatumumab in Previously Untreated CLL/SLL  (View details on II
13-165A Pilot Study of Oncaspar + Dexamethasone in Patients with Relapsed or Refractory T-Cell Lymphoma  (View details on
14-159A Single-Arm, Open-Label Phase 2 Study of Nivolumab (BMS-936558) in Subjects with Relapsed or Refractory Follicular Lymphoma (FL)  (View details on II
13-592A041202: A Randomized Phase III Study of Bendamustine Plus Rituximab Versus Ibrutinib Plus Rituximab Versus Ibrutinib Alone in Untreated Older Patients (≥ 65 Years of Age) with Chronic Lymphocytic Leukemia (CLL)  (View details on III
12-188BMT CTN 1101: A Multi-Center, Phase III, Randomized Trial of Reduced Intensity (RIC) Conditioning and Transplantation of Double Unrelated Umbilical Cord Blood (dUCB) versus HLA-Haploidentical Related Bone Marrow (haplo-BM) for Patients with Hematologic Malignancies  (View details on III
10-327CALGB 50801: Phase II Trial of Response-Adapted Therapy Based on Positron Emission Tomography (PET) for Bulky Stage I and Stage II Classical Hodgkin Lymphoma (HL)  (View details on II
14-096Carfilzomib plus Belinostat in Relapsed/Refractory Non-Hodgkin Lymphoma Subtypes: A Phase I Study  (View details on I
14-242Non-Comparative, Two-Cohort, Single Arm, Open-label, Phase 2 Study of Nivolumab (BMS-936558) in Classical Hodgkin Lymphoma (cHL) Subjects after Failure of Autologous Stem Cell Transplant (ASCT)  (View details on II
14-051Open-Label, Uncontrolled Phase II Trial of Intravenous PI3K Inhibitor BAY 80-6946 in Patients with Relapsed, Indolent or Aggressive Non-Hodgkin's Lymphomas  (View details on II
15-196Phase II Study of Brentuximab Vedotin Plus AD in Non-bulky Limited Stage Hodgkin Lymphoma  (View details on II
10-116Phase II Study of Dose-Adjusted EPOCH-Rituxan in Adults with Untreated Burkitt Lymphoma and c-MYC Positive Diffuse Large B-Cell Lymphoma  (View details on II
21 clinical trials listed.

Through our founding membership in the Dana-Farber/Harvard Cancer Center, an NCI-designated Comprehensive Cancer Center, these clinical trials are conducted at the Massachusetts General Hospital Cancer Center and may be available at other partner institutions.